Innovating Works

eVai

Financiado
A novel bioinformatics SaaS platform to identify and classify the pathogenicity...
A novel bioinformatics SaaS platform to identify and classify the pathogenicity of single genomic variants and oligogenic variant combinations for the diagnosis and treatment of genetic dise Genetic diseases affect +300 million individuals worldwide, resulting in 2.8 million new patients every year. The advent of Next Generation Sequencing (NGS) means it’s now possible to analyze the whole patient’s genome. However, v... Genetic diseases affect +300 million individuals worldwide, resulting in 2.8 million new patients every year. The advent of Next Generation Sequencing (NGS) means it’s now possible to analyze the whole patient’s genome. However, variant interpretation is the biggest hindrance to widespread adoption of NGS technologies. Hence, clinicians are struggling to identify disease-causing variants and the diagnostic yield of genetic disorders is only about 50% on average. eVai is a revolutionary SaaS platform that allows geneticists to identify multiple pathogenic genomic variants with unprecedented accuracy and speed. We bring to market [1] first and only digenic and oligogenic variant interpretation [2] best predictive causative variants accuracy; [3] reduced turnaround time; and [4] consistency of variant interpretation; [5] discovery of unknown variants. ver más
31/03/2024
ENGENOME SRL
2M€
Perfil tecnológico estimado
Duración del proyecto: 23 meses Fecha Inicio: 2022-04-28
Fecha Fin: 2024-03-31

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-03-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
HORIZON-EIC-2021-ACCELERATORCHALLENGES-01-01: Strategic Digital and Health Technologies
Cerrada hace 2 años
Presupuesto El presupuesto total del proyecto asciende a 2M€
Líder del proyecto
ENGENOME SRL No se ha especificado una descripción o un objeto social para esta compañía.